Jennifer J. Rhodes - 14 Dec 2021 Form 4 Insider Report for Angion Biomedica Corp. (ELTX)

Role
Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary
Signature
/s/ Jennifer J. Rhodes
Issuer symbol
ELTX
Transactions as of
14 Dec 2021
Net transactions value
-$1,090
Form type
4
Filing time
15 Dec 2021, 15:06:37 UTC
Previous filing
16 Nov 2021
Next filing
04 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELTX Common Stock Sale $1,090 -451 -1.5% $2.42* 30,399 14 Dec 2021 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares reported in this Form 4 were sold pursuant to a 10b5-1 trading plan adopted by the reporting person solely to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs") granted by the Issuer.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.41 to $2.42 inclusive.

Remarks:

Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary